Treating Liver Fibrosis in 2025: Prime Time or Are We Still in the Commercial Break?

Nov 16 2024
Convention Center: Ballroom 6C
8:00 AM - 9:30 AM
Captured

World Class Speakers

RS
Presenter

Robert Schwabe, MD

Columbia University
Scott L. Friedman, MD, FAASLD
Presenter

Scott L. Friedman, MD, FAASLD

Icahn School of Medicine at Mount Sinai (ISMMS)
Manal F Abdelmalek, MD, MPH, FAASLD
Presenter

Manal F Abdelmalek, MD, MPH, FAASLD

Mayo Clinic Rochester
Jonathan A Fallowfield, BSc, BM, PhD, MRCP
Presenter

Jonathan A Fallowfield, BSc, BM, PhD, MRCP

University of Edinburgh
Meena B Bansal, MD, FAASLD
Moderator

Meena B Bansal, MD, FAASLD

Icahn School of Medicine at Mount Sinai (ISMMS)
Enis Kostallari, PhD, MS
Moderator

Enis Kostallari, PhD, MS

Mayo Clinic Rochester

Description

This program reviews recent updates in the rapidly evolving area of liver fibrosis treatment. Topics addressed by the expert presenters include an overview of the different therapeutic targets from metabolism to matrix; the goal of reversing rather than halting liver fibrosis; restoration of liver function in addition to antifibrogenic treatment and novel concepts that link the two; and personalized and combination therapy with a specific focus on metabolism.

Objectives

  • List different treatment options for hepatic fibrosis.
  • Review the underlying mechanisms of hepatic fibrosis reversibility and restoration of liver function, and how this can be achieved in patients.
  • Identify personalized treatments as well as combination and sequential therapies for hepatic fibrosis.